Research Article

CD44, IL-33, and ST2 Gene Polymorphisms on Hepatocellular Carcinoma Susceptibility in the Chinese Population

Xiaolan Pan,¹ Meiqin Li,¹ Lei Huang,¹ Dan Mo,² Yihua Liang,¹ Zhaodong Huang,¹ Bo Zhu,¹ and Min Fang¹

¹Department of Clinical Laboratory, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, 530021 Guangxi, China

²Department of Surgery, Maternal and Child Health Hospital of the Guangxi Zhuang Autonomous Region, Nanning, China

Correspondence should be addressed to Min Fang; sunflowersun@126.com

Received 19 May 2020; Revised 24 August 2020; Accepted 17 September 2020; Published 29 September 2020

Academic Editor: Ernesto S. Nakayasu

Copyright © 2020 Xiaolan Pan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The interleukin- (IL-) 33/ST2 axis plays a pivotal role in tumorigenesis through influencing cancer stemness and other mechanisms. CD44 is one of the critical markers of hepatocellular carcinoma (HCC) among the cancer stem cells (CSCs). There is still a lack of CD44 gene single-nucleotide polymorphisms (SNPs) combined with IL-33/ST2 pathway single-nucleotide polymorphisms in HCC susceptibility analysis literature, although CD44 and IL-33/ST2 have been reported separately in human cancers. This study is aimed at investigating the relationship between CD44, IL-33, and ST2 SNPs and HCC susceptibility and clinicopathological features. We analyzed 565 HCC patients and 561 healthy controls in the Chinese population. The genes for CD44rs187115A>G, IL-33 rs1929992A>G, and ST2 rs3821204G>C were typed using the SNaPshot method. We found that the distribution frequencies of CD44 and ST2 alleles and genotypes in both the HCC case group and the control group were statistically significant ($p < 0.05$). The results showed that individuals carrying at least one G allele of the CD44 rs187115 gene were at a higher risk than the AA genotype carriers ($p = 0.007$, odds ratio (OR) = 1.429, 95% confidence interval (CI): 1.102–1.854). Similarly, individuals with at least one C allele of ST2 rs3821204 had a higher risk of HCC than those with GG genes ($p \leq 0.001$, OR = 1.647, 95% CI: 1.296–2.093). Combining the haplotype analysis of the 3 loci suggested that CD44 rs187115, IL-33 rs1929992, and ST2 rs3821204 are associated with the risk of HCC and could potentially serve as useful genetic markers for HCC in some populations of China.

1. Introduction

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. The annual global incidence of primary liver cancer is 841,000; the death rate is 782,000; and it is the second highest mortality rate among males [1]. The mortality rate of liver cancer in China is the second highest among malignant tumors (new liver cancer accounts for more than 50% of the world's total) and is following a trend of annual increase [2]. Surgical resection, liver transplantation, and tumor ablation are the potential curative therapies; however, these treatment options are only applicable to patients in the early stage of disease [3, 4]. Due to the highly malignant potential of HCC, diagnosis is not usually made until an advanced stage, at which point there are no effective

therapies to be offered [5]. Therefore, it is of pressing importance to identify which genes are responsible for susceptibility to HCC. Single-nucleotide polymorphism (SNP), a well-defined molecular biomarker, has been widely applied in HCC susceptibility evaluation [6, 7].

Various factors, including viral infection and cirrhosis, may be involved in the development of HCC [8, 9]. Tumor stem cells (CSCs), a small number of stem cell-like cancer cell subsets in tumor tissues, are characterized by both cancer cells and stem cells and are decisive in the initiation of HCC formation, growth, and metastasis [10, 11]. The CSC marker CD44 is essential in several malignancies, including HCC, and is the primary adhesion molecule of the extracellular matrix, playing a pivotal role in tumor cell differentiation, invasion, and metastasis [12, 13]. Recent studies have

TABLE 1: SNP oligonucleotide sequences used for related gene genotyping.

SNP	PCR primer
CD44 rs187115	Forward: 5'-TCAGGCAGGAGGAATAGGACA-3' Reverse: 5'-CTCCTGCCCAATAAAGCCAA-3'
IL-33 rs1929992	Forward: 5'-TATGACACAGGACCCCGGAA-3' Reverse: 5'-GAAGTCATCATCAACTTGAACCT-3'
ST2 rs3821204	Forward: 5'-GACTGTTCTGTTTGTCTGGGA-3' Reverse: 5'-TTGTTCACTTTACCACCCTCGC-3'

suggested that in the development of HCC, *CD44*⁺ cells were entwined with the genetic processes involved in cancer invasion and metastasis [14, 15]. HCC was often detected following the onset of cirrhosis, and the majority of patients worldwide with HCC have underlying cirrhosis [16]. The *IL-33* gene, located on chromosome 9 (9p24.1), binds to *ST2* and forms a trimer with IL-1R accessory protein (IL-1RAcP), which recruits downstream signaling molecules through the Toll/IL-1R (TIR) domains of *ST2*. The signaling pathways of nuclear factor kappaB (NF- κ B), activator protein 1 (AP-1), and mitogen-activated protein kinase (MAPK) are then activated, and the subsequent upregulation of the gene expression of proinflammatory cytokines leads to hepatic fibrosis [17–19]. Although *CD44* and *IL-33/ST2* have been well documented in human cancer metastasis or prognosis, respectively, evidence of the *CD44* gene SNPs combined with *IL-33/ST2* pathway functional polymorphisms in HCC susceptibility and clinical characteristics is scarce. We aimed to investigate in this study the association of these 3 polymorphisms with demographics, etiology, clinical features, and susceptibility to HCC.

2. Materials and Methods

2.1. Subjects and Clinical Data. The participant cohort was continuously recruited from September 2016 to December 2018 at the Affiliated Tumor Hospital of Guangxi Medical University. All patients were newly diagnosed and pathologically confirmed as having HCC, according to the American Association for the Study of Liver Diseases guidelines [20]. Ultimately, the study included 565 participants in the case group, 487 males and 78 females, aged 10–89 years. The control group was matched for sex and age and included a total of 561 cases (male = 488, female = 73), aged 22–78 years. The healthy control group patients were free of hypertension, diabetes, dyslipidemia, liver diseases, and cancer. Demographic data included medical record number, gender, age, drinking history, smoking history, tumor stage, and related biochemical indicators. All participants signed a written consent form after being informed of the study details. The Judging Committee approved the study of the Affiliated Tumor Hospital of Guangxi Medical University.

2.2. DNA Extraction and Genotyping Assays. We collected 2 ml of fasting peripheral blood from each participant and placed it in ethylenediaminetetraacetic acid- (EDTA-) K2 anticoagulant tube. After thorough mixing, it was stored in

a refrigerator at -80°C for DNA extraction from the genome. Genomic DNA was extracted from the 2 ml of peripheral blood using a commercial kit according to the manufacturer's instructions (Adelaide, Beijing, China) and stored at -80°C before genotyping. The genotyping of *CD44* rs187115, *IL-33* rs1929992, and *ST2* rs3821204 was performed using the SNaPshot method as previously described [21], and negative controls were used in each test to ensure accuracy of the genotype evaluation. The primers are listed in Table 1.

2.3. Statistical Analysis. First, we assessed whether genotype frequencies were in the Hardy-Weinberg equilibrium (HWE). The Pearson two-sided chi-squared (χ^2) test was used to analyze the HWE law to confirm whether the population of the study samples was representative of the populace [22]. When a $p > 0.05$ value was observed, the samples were representative of the population. Then, the χ^2 test was used to examine the difference in clinicopathological features between the case group and the control group. The distribution data of alleles and genotypes were compared using the χ^2 test and logistic regression analysis, and the relative risk was expressed by odd ratios (OR) and their 95% confidence intervals (CI). Additionally, unconditional logistic regression was used to correct the effects of confounding factors such as gender, age, drinking history, and smoking history on OR values and 95% CI. The haploid model analysis of the gene interaction was performed using the SHEsis software (<http://analysis.bio-x.cn/myAnalysis.php>) [23]. eQTL are regions of the genome containing DNA sequence variants that influence the expression level of one or more genes. We further explored the effects of the three significant SNPs (*CD44* rs187115, *IL-33* rs1929992, and *ST2* rs3821204) on their gene expression by investigating a public database, GTEx portal (<https://gtexportal.org/>) [24]. Statistical analysis of the data was performed using the statistical software package SPSS 24.0 (SPSS Inc., IBM, Chicago, IL, USA), and the test was performed using a two-sided test with a test level of $\alpha = 0.05$. We used the false positive reporting probability (FPRP) to evaluate meaningful findings. We set 0.2 as the FPRP threshold, and 0.1 as the prior probability to detect the preponderance ratio (OR) associated with genotypes and haplotypes in the study to be 0.67/1.50 (protection/risk effect). Only significant results with an FPRP value of < 0.2 would be considered a noteworthy finding.

3. Results

3.1. Demographic and Clinical Characteristics of Participants. Initially, 593 subjects were enrolled in the HCC group, 21 cases had no pathological reports, and 7 cases had other cancers, and thus 28 cases were excluded. Ultimately, the study included 565 patients in the HCC group (males = 487, females = 78, age 10–89 years) and 561 in the healthy control group (males = 488, females = 73, age 22–78 years). Briefly, male participants showed a higher prevalence of HCC than females (487 vs. 78). Metastasis was found in 85 patients (15.0%). Stage of HCC was staged A or B in 259 patients (45.8%) and stage C or D in 306 patients (54.2%). Moreover,

TABLE 2: General characteristics of HCC patients and the normal controls.

Characteristics	Cases (n = 565)	Controls (n = 561)	p value
Age (year)			0.546
Range	10-89	22-78	
Mean	53.62	52.15	
<40	95	102	
41-50	133	152	
51-60	186	176	
>60	151	131	
Gender			0.453
Male	487	488	
Female	78	73	
BMI (kg/m ²)			0.406
<18.5	62	51	
18.5-23.9	366	359	
≥24	137	151	
Smoking status			0.734
No	344	336	
Yes	221	225	
Alcohol drinker			0.113
No	374	396	
Yes	191	165	
HBV infection			
HbsAg (-)	47	479	
HbsAg (+)	497	75	≤0.001
Liver cirrhosis			
Absent	487	491	
Present	78	70	0.51
BCLC stage			
A+B stage	259		
C+D stage	306		
Metastasis			
No	480		
Yes	85		

there were no statistical differences in the distributions of age, gender, smoking status, and alcohol consumption between the 2 groups. Detailed demographic and clinical characteristics of the study participants, including age, gender, smoking and drinking status, Barcelona clinic liver cancer (BCLC) stage, and metastasis status, are provided in Table 2.

3.2. Association between CD44 rs187115 and Susceptibility and Clinicopathological Parameters of HCC. In this study, the distribution of CD44 gene rs187115 in the HCC group ($p = 0.58$) and the control group ($p = 0.74$) was consistent with the HWE. The frequency distribution differences of the GG, GA, and AA genotypes in the 2 groups were statistically significant ($p = 0.010$). We used the AA genotype and A allele as a reference to analyze the risk of HCC. Logistic regression was used to adjust the impact of confounding fac-

tors such as gender and age and for calculating the OR value of rs187115 on the risk of HCC and 95% CI. Ultimately, it was found that compared with other genotype individuals, people carrying the homozygous GG genotype were 2.469 times more likely to develop HCC than those carrying the AA gene ($p = 0.027$, adjusted OR (OR_{adj}) = 2.469, 95% CI: 1.110–5.492). Furthermore, individuals who carried the heterozygous AG genotype were 1.359 times more likely to develop HCC than individuals carrying the GG gene ($p = 0.026$, $OR_{adj} = 1.359$, 95% CI: 1.039–1.778). Moreover, compared with the A allele, individuals carrying the G allele had a 1.423 times higher risk of HCC ($p = 0.003$, OR = 1.423, 95% CI: 1.131–1.792), suggesting that the G allele mutation was associated with an increased risk of HCC. The CD44 rs187115 polymorphism genotype and allele frequencies for the HCC and control groups are listed in Table 3. Also, we further studied the clinical status of CD44 rs187115 gene polymorphism in HCC to assess whether there was a difference in the distribution of the rs187115 genotype among clinical subgroups. The results showed that the distribution of AG and GG genotypes of rs187115 in the hepatic fibrosis subgroup was significantly different ($p = 0.038$) (Table 4).

3.3. Association between IL-33 rs1929992 and Susceptibility and Clinicopathological Parameters of HCC. The distribution of IL-33rs1929992 locus genotype in the HCC group ($p = 0.084$) and the control group ($p = 0.750$) was consistent with HWE, which indicates a good representation of the population. There was no significant difference in the frequency distribution of the GG, GA, and AA genotypes between the 2 groups ($p = 0.597$). Additionally, the results showed that rs1929992 genotyping of GA, G vector, and G allele was not associated with the risk of HCC (Table 3). Furthermore, there were no significant associations between IL-33 rs1929992 and any of the clinicopathological parameters (Table 5).

3.4. Association between ST2 rs3821204 and Susceptibility and Clinicopathological Parameters of HCC. The observed genotype frequency of ST2 rs3821204 was consistent with the expected distribution of HWE in both the HCC group ($p = 0.071$) and the control group ($p = 0.125$). The frequency distribution of the GG, CG, and CC genotypes in the 2 groups was statistically significant ($p \leq 0.001$). The risk of HCC development was analyzed using the AA genotype and the A allele as a reference. After adjusting for gender and age using logistic regression, we calculated the OR value and 95% CI of rs187115 locus for the risk of HCC. Finally, the results showed that individuals with rs3821204 CG+CC genotype were 1.647 times more at risk of developing HCC than those with the GG genotype ($p \leq 0.001$, $OR_{adj} = 1.647$, 95% CI: 1.296–2.093) (Table 3). Similarly, individuals carrying the homozygous CC genotype were 2.208 times more likely to develop HCC than individuals carrying the GG gene ($p \leq 0.001$, $OR_{adj} = 2.208$, 95% CI: 1.548–3.149). Furthermore, individuals who carried the heterozygous CG genotype were 1.483 times more likely to develop HCC than individuals

TABLE 3: Distribution and genotype frequencies of related polymorphisms in the HCC group and the control group.

Parameter	Case, <i>n</i> (%)	Controls, <i>n</i> (%)	OR (95% CI)	<i>p</i> _{OR}	OR _{adj} (95% CI)	<i>p</i> _{ORadj}
CD44 rs187115						
All						
AA	383 (67.8)	421 (75.0)	1.00		1.00	
AG	162 (28.7)	131 (23.4)	1.359 (1.039-1.778)	0.025	1.359 (1.039-1.778)	0.026
GG	20 (3.5)	9 (1.6)	2.443 (1.099-5.430)	0.028	2.469 (1.110-5.492)	0.027
AG+GG	182 (32.2)	140 (25.0)	1.429 (1.101-1.855)	0.007	1.429 (1.102-1.854)	0.007
Alleles						
A	928 (82.1)	973 (86.7)	1.00		1.00	
G	202 (17.9)	149 (13.3)	1.421 (1.129-1.789)	0.003	1.423 (1.131-1.792)	0.003
IL-33 rs1929992						
All						
AA	169 (29.9)	157 (28.0)	1.00		1.00	
GA	261 (46.2)	276 (49.2)	0.879 (0.667-1.157)	0.357	0.886 (0.672-1.168)	0.390
GG	135 (23.9)	128 (22.8)	0.980 (0.708-1.356)	0.902	0.980 (0.708-1.358)	0.906
AG+GG	396 (70.1)	404 (72.0)	0.911 (0.704-1.178)	0.476	0.916 (0.708-1.186)	0.506
Alleles						
A	599 (53.0)	590 (52.6)	1.00		1.00	
G	531 (47.0)	532 (47.4)	0.983 (0.833-1.160)	0.840	0.984 (0.834-1.161)	0.848
ST2 rs3821204						
All						
GG	198 (35.0)	264 (47.1)	1.00		1.00	
CG	255 (45.2)	230 (41.0)	1.478 (1.144-1.910)	0.003	1.483 (1.147-1.916)	0.003
CC	112 (19.8)	67 (11.9)	2.229 (1.564-3.177)	≤0.001	2.208 (1.548-3.149)	≤0.001
CG+CC	367 (65.0)	297 (52.9)	1.648 (1.297-2.093)	≤0.001	1.647 (1.296-2.093)	≤0.001
Alleles						
G	631 (56.0)	690 (61.5)	1.00		1.00	
C	499 (43.0)	432 (38.5)	1.532 (1.290-1.820)	≤0.001	1.527 (1.285-1.813)	≤0.001

OR: odds ratio; OR_{adj}: adjusted odds ratio; CI: confidence interval.

carrying the GG gene ($p = 0.003$, OR_{adj} = 1.483, 95% CI: 1.147–1.916). Moreover, compared with the G allele, individuals carrying the C allele had a 1.532 times higher risk of HCC ($p \leq 0.001$, OR = 1.527, 95% CI: 1.285–1.813), suggesting that the C allele mutation was associated with an increased risk of HCC. Also, we further studied the clinical status of ST2 rs3821204 gene polymorphism in HCC; however, there was no significant difference in the distribution of the ST2 rs3821204 genotype in the clinical subgroup analysis ($p > 0.05$) (Table 6).

3.5. Haplotype Frequencies. Results obtained from SHEsis software suggested that the 3 SNPs (CD44, IL-33, and ST2) were in a strong linkage disequilibrium. The risk of HCC was affected when cooccurrence of these polymorphisms was examined using logistic regression analysis. We found 3 haplotypes to be associated with the risk of HCC. Compared to participants with other haplotypes, carrying the rs187115-rs1929992-rs3821204 G-G-C haplotype increased the risk of HCC by 3.181 times ($p \leq 0.001$, OR = 3.181, 95%CI = 1.664-6.082). The results of haplotype frequencies are summarized in Table 7, and Table 8 shows the FPRP values of significant results at different prior probability

levels because their probability of being a false positive result was <20%.

3.6. Expression Quantitative Trait Loci. We further explored biological effects of the three significant SNPs (CD44 rs187115, IL-33 rs1929992, and ST2 rs3821204) on their gene expression by investigating a public database (GTEx portal). We found that genotypes of these SNPs were not associated with their gene expression in liver tissue and whole blood cells.

4. Discussion

In this study, the results showed that the distribution frequency of the CD44 rs187115 allele and genotype in the HCC case group and the control group was statistically significant ($p < 0.05$), which was consistent with the results of Liu et al. in lung cancer and Winder et al. in gastric adenocarcinoma [25, 26]. Also, we further showed that there was a significant difference in the distribution of the rs187115 and GG genotypes in the liver fibrosis subgroup. CD44 belongs to the family of adhesion molecules and is also a hyaluronic acid receptor, which means it is mainly involved in the adhesion

TABLE 4: Association of CD44 rs187115 genotype with clinical characteristics in HCC patients.

Characteristics	rs187115			<i>p</i> value	rs187115			<i>p</i> value	rs187115		<i>p</i> value
	AA	AG	GG		AG	GG	AA		AG+GG		
Age (year)											
<40	147	57	6		57	6		147	63		
≥40	235	106	14	0.589	106	14	0.659	235	120	0.351	
Gender											
Male	55	20	3		20	3		55	23		
Female	327	143	17	0.800	143	17	0.728	327	160	0.563	
BMI (kg/m ²)											
<18.5	43	16	4		16	4		43	20		
18.5-23.9	242	109	14		109	14		242	123		
≥24	97	38	2		38	2		97	40		
BCLC stage											
A+B stage	211	83	11		83	11		211	94		
C+D stage	171	80	9	0.634	80	9	0.730	171	89	0.373	
Smoking status											
No	230	100	12		100	12		230	112		
Yes	152	63	8	0.973	63	8	0.907	152	71	0.840	
Alcohol drinker											
No	251	107	15		107	15		251	122		
Yes	131	56	5	0.692	56	5	0.402	131	61	0.838	
Metastasis											
No	272	181	17		181	17		272	198		
Yes	71	21	3	0.008	21	3	0.545	71	24	0.002	
Liver cirrhosis											
Absent	116	53	2		53	2		116	55		
Present	266	110	18	0.117	110	18	0.038	266	128	0.955	
HBV infection											
HbsAg (–)	37	18	1		18	1		37	19		
HbsAg (+)	339	141	18	0.675	141	18	0.419	339	159	0.754	
HCV infection	6	4	1		4	1		6	5		
AST											
Negative	204	79	9		79	9		204	88		
Positive	178	84	11	0.460	84	11	0.770	178	95	0.226	
ALT											
Negative	235	163	12		163	12		235	175		
Positive	147	67	8	≤0.001	67	8	0.309	147	75	0.031	
GGT											
Negative	130	66	8		66	8		130	74		
Positive	252	97	12	0.322	97	12	0.966	252	109	0.132	
AFP											
Negative	154	62	11		62	11		154	73		
Positive	228	101	9	0.343	101	9	0.144	228	120	0.580	

ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: γ-glutamyl transpeptidase; AFP: alpha fetoprotein.

between cells and the interstitial matrix [27]. It was reported that *CD44* promoted HCC CSC stemness by regulating natural killer (NK) sensitivity or the tyrosine-protein kinase-Met-class I phosphoinositide 3-kinase-protein kinase B (c-Met-PI3K-AKT) signaling cascade, leading to poor prognoses of

cancer and chemoresistance [28, 29]. Additionally, *CD44* is involved in the maintenance of CSCs in HCC, possibly through the PI3K/AKT/mTOR pathway and the NOTCH3 signaling pathway [30]. In some genes, an SNP located in a coding, promoter, or regulatory region, may have a certain

TABLE 5: Association of IL-33 rs1929992 genotype with clinical characteristics in HCC patients.

Characteristics	rs1929992			<i>p</i> value	rs1929992		<i>p</i> value	rs1929992		<i>p</i> value
	AA	GA	GG		GA	GG		AA	GA+GG	
Age(year)										
Range	13-83	10-89	24-87		10-89	24-87		13-83	10-89	
Mean	52.6	52.1	54.3		52.1	54.3		52.6	53.1	
<40	23	51	15		51	15		23	663	
≥40	146	210	120	0.056	210	120	0.053	146	330	0.057
Gender										
Male	138	233	116		233	116		138	349	
Female	31	28	19	0.082	28	19	0.329	31	47	0.051
BMI (kg/m ²)										
<18.5	15	32	14		32	14		15	46	
18.5-23.9	112	164	90		164	90		112	254	
≥24.0	42	65	31	0.816	65	31	0.735	42	96	0.182
BCLC stage										
A+B stage	90	145	71		145	71		90	216	
C+D stage	79	116	64	0.821	116	64	0.575	79	180	0.778
Smoking status										
No	98	166	80		166	80		98	246	
Yes	71	95	55	0.460	95	55	0.453	71	150	0.357
Alcohol drinker										
No	114	178	88		178	88		114	266	
Yes	55	83	47	0.831	83	47	0.398	55	130	0.948
Metastasis										
No	143	218	119		218	119		143	337	
Yes	26	43	16	0.470	43	16	0.221	26	59	0.882
Family history of cancer										
No	145	219	121		219	121		145	340	
Yes	24	42	14	0.302	42	14	0.121	24	56	0.985
Liver cirrhosis										
Absent	47	89	35		89	35		47	124	
Present	122	172	100	0.173	172	100	0.096	122	272	0.404
HBV infection										
HbsAg (−)	18	23	14		23	14		18	37	
HbsAg (+)	146	225	128		225	128		146	353	
HCV infection	5	3	3	0.684	3	3	0.792	5	6	0.379
AST										
Negative	82	135	76		135	76		82	211	
Positive	87	126	59	0.402	126	59	0.387	87	185	0.300
ALT										
Negative	97	155	94		155	94		97	249	
Positive	72	106	41	0.066	106	41	0.056	72	147	0.221
GGT										
Negative	65	106	56		106	56		65	162	
Positive	104	155	79	0.855	155	79	0.868	104	234	0.587
AFP										
Negative	67	108	53		108	53		67	161	
Positive	102	153	82	0.886	153	82	0.684	102	235	0.822

ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ -glutamyl transpeptidase; AFP, alpha fetoprotein.

TABLE 6: Association of ST2 rs3821204 genotype with clinical characteristics in HCC patients.

Characteristics	rs3821204			<i>p</i> value	rs3821204		<i>p</i> value	rs3821204		<i>p</i> value
	GG	CG	CC		CG	CC		GG	CG+CC	
Age(year)										
Range	10-78	19-87	24-89		19-87	24-89		10-78	19-89	
Mean	52.8	52.2	52.9		52.2	52.9		52.8	52.6	
<40	28	36	15		36	15		28	51	
>40	170	220	97	0.981	220	97	0.864	170	317	0.926
Gender										
Male	176	219	92		219	92		176	311	
Female	22	36	20	0.250	36	20	0.359	22	56	0.173
BMI (kg/m ²)										
<18.5	21	30	11		30	11		21	41	
18.5-23.9	125	168	74		168	74		125	242	
≥24.0	52	57	27	0.883	57	27	0.832	52	84	0.670
BCLC stage										
A+B stage	110	131	64		131	64		110	195	
C+D stage	88	124	48	0.501	124	48	0.308	88	172	0.582
Smoking status										
No	123	152	68		152	68		123	220	
Yes	75	103	44	0.863	103	44	0.842	75	147	0.613
Alcohol drinker										
No	131	165	77		165	77		131	242	
Yes	67	90	35	0.752	90	35	0.452	67	125	0.958
Metastasis										
No	122	211	95		211	95		122	306	
Yes	17	44	17	0.417	44	17	0.623	17	61	0.222
Family history of cancer										
No	167	221	96		221	96		167	317	
Yes	31	34	16	0.783	34	16	0.807	31	50	0.511
Liver cirrhosis										
Absent	62	77	31		77	31		62	108	
Present	136	178	81	0.798	178	81	0.626	136	259	0.641
HBV infection										
HbsAg (−)	16	11	11		11	11		16	22	
HbsAg (+)	179	239	99		239	99		179	338	
HCV infection	3	5	2	0.304	5	2	0.144	3	7	0.617
AST										
Negative	108	127	60		127	60		108	187	
Positive	90	128	52	0.575	128	52	0.506	90	180	0.415
ALT										
Negative	121	148	75		148	75		121	223	
Positive	77	107	37	0.271	107	37	0.107	77	144	0.936
GGT										
Negative	90	95	42		95	42		90	137	
Positive	108	160	70	0.821	160	70	0.964	108	230	0.060
AFP										
Negative	83	99	44		99	44		83	143	
Positive	115	156	68	0.789	156	68	0.933	115	224	0.494

ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: γ -glutamyl transpeptidase; AFP: alpha fetoprotein.

TABLE 7: The association of haplotype of each gene with hepatocellular cancer risk.

Haplotype	Case (%) <i>N</i> = 565	Control (%) <i>N</i> = 561	<i>p</i>	OR (95% CI)
rs187115-rs1929992-rs3821204				
AAC	227.91 (0.202)	168.09 (0.150)	0.001	1.434 (1.152, 1.785)
AAG	264.26 (0.234)	343.55 (0.306)	≤0.001	0.692 (0.574, 0.834)
AGC	168.53 (0.149)	149.51 (0.133)	0.279	1.140 (0.899, 1.446)
AGG	267.30 (0.237)	310.86 (0.277)	0.027	0.808 (0.669, 0.977)
GAC	44.16 (0.039)	34.13 (0.030)	0.261	1.296 (0.823, 2.042)
GAG	62.66 (0.055)	44.23 (0.039)	0.073	1.431 (0.965, 2.122)
GGC	38.40 (0.034)	12.27 (0.011)	≤0.001	3.181 (1.664, 6.082)
GGG	56.77 (0.050)	59.36 (0.053)	0.774	0.947 (0.652, 1.376)
rs187115, rs3821204				
AC	396.22 (0.351)	318.60 (0.284)	≤0.001	1.362 (1.139, 1.627)
AG	531.77 (0.471)	653.40 (0.582)	≤0.001	0.638 (0.540, 0.753)
GC	82.77 (0.073)	45.40 (0.040)	≤0.001	1.874 (1.292, 2.719)
GG	119.23 (0.106)	104.60 (0.093)	0.330	1.147 (0.870, 1.513)
rs187115, rs1929992				
AA	492.04 (0.435)	511.85 (0.456)	0.321	0.919 (0.779, 1.086)
AG	435.96 (0.386)	460.15 (0.410)	0.238	0.903 (0.763, 1.070)
GA	106.96 (0.095)	78.15 (0.070)	0.031	1.396 (1.030, 1.893)
GG	95.04 (0.084)	71.85 (0.064)	0.069	1.342 (0.976, 1.845)
rs1929992, rs3821204				
AC	271.98 (0.241)	200.95 (0.179)	0.003	1.453 (1.184, 1.783)
AG	327.02 (0.289)	389.05 (0.347)	0.003	0.767 (0.642, 0.917)
GC	207.02 (0.183)	163.05 (0.145)	0.015	1.319 (1.054, 1.651)
GG	323.98 (0.287)	368.95 (0.329)	0.030	0.820 (0.686, 0.981)

TABLE 8: False positive report probability values for associations between the risk of HCC and the frequency of genotypes and haplotypes of the CD44 gene and ST2 gene in an Chinese population.

Genotype/haplotype	OR (95% CI)	<i>p</i> value	Statistical power ^a	Prior probability				
				0.25	0.1	0.01	0.001	0.0001
CD44 rs187115								
AG/AA	1.359 (1.039-1.778)	0.025	0.764	0.091	0.232	0.796	0.971	0.997
GG/AA	2.443 (1.099-5.430)	0.028	0.116	0.429	0.693	0.961	0.996	1.000
AG+GG/AA	1.429 (1.101-1.855)	0.007	0.642	0.034	0.095	0.563	0.921	0.991
ST2 rs3821204								
CG/GG	1.478 (1.144-1.910)	0.003	0.545	0.016	0.046	0.345	0.842	0.982
CC/GG	2.229 (1.564-3.177)	≤0.001	0.014	0.002	0.006	0.065	0.411	0.875
CG+CC/GG	1.648 (1.297-2.093)	≤0.001	0.220	0.001	0.002	0.020	0.168	0.668

^aStatistical power was calculated using the number of observations in the subgroup and the OR and *p* values in this table.

function, whereas *CD44* SNP rs187115 is located in the first intron of *CD44* [31, 32]. Until this point, the regulatory mechanism of *CD44* intron 1 has not been reported, but it has been found that the polymorphism of the *CD44* rs187115 gene may act on chemical resistance and cellular stress response in a p53-dependent manner in HCC [33].

As a bifunctional factor, *IL-33* has both transcription factors and cytokine activity [34]. There is a strong correlation between the level of *IL-33* and the progression of disease in a variety of malignant epithelial tumors [19, 35]. Previous

studies have shown that rs1929992 was associated with the risk of several autoimmune diseases. Since it is functional and has not reported its relationship to HCC, we studied whether it is associated with HCC risk [36–38]. However, the results showed that the difference in distribution frequency of rs1929992 locus alleles and genotypes in the HCC case group and control group was not statistically significant ($p > 0.05$), which was similar to the findings of Jafarzadeh et al. in breast cancer [39]. Some studies have reported overexpression of *IL-33* in colorectal cancer [19, 40], while in

HCC, inconsistent results were observed. Zhang et al. found that increased *IL-33* protein levels were present in HCC patients' serum and liver tissue [41], whereas Bergis et al. did not find a significant difference in *IL-33* serum levels between HCC patients and healthy controls [42]. Thus, further replication studies with larger sample sizes are needed to identify the relationship of rs1929992 to the risk of HCC.

Recent studies have also found that soluble *ST2* levels were highly expressed in the liver, lung, and breast cancer; malignant glioma; and other tumor tissues; this was associated with the occurrence, invasion, and metastasis of tumors [43–45]. In the present study, we found that the frequency of the *ST2* rs3821204 C allele was higher in the HCC group than in the healthy control group; our results were consistent with the findings of Wei et al. on Chinese HCC patients [46]. The *ST2* rs3821204 is located in the three prime untranslated regions (3'UTR) of *sST2* mRNA, and the CC genotype of rs3821204 is highly correlated with elevated plasma *sST2* levels in vivo [47]. The *ST2* rs3821204 CC genotype may contribute to hepatocarcinogenesis by enhancing *ST2* production at the transcriptional and translational levels [46]. The physiological effect of *ST2* gene rs3821204 polymorphism on HCC patients is mainly exerted by enhancing the synthesis of *ST2* protein [46]. Additionally, studies have shown that *ST2* deficiency could prevent tumor progression in a mouse model [48]. Based on the above mechanisms, individuals with rs3821204 are prone to develop HCC.

In this study, by performing a haplotype analysis, we found that *CD44* rs187115, *IL-33* rs1929992, and *ST2* rs3821204 have a combined effect on HCC susceptibility. By analyzing the reasons, the development of HCC was related to various genetic polymorphisms, and changes in multiple genes could cause genetic and molecular abnormalities [49, 50]. There are several studies related to the *IL-33/ST2* axis and CSCs [51, 52]. Our previous research clarified that *IL-33* binds to its receptor *ST2* and induces phosphorylation of c-Jun N-terminal kinase activation (JNK), which leads to the expansion of colon cancer cell stemness [19]. Also, some researchers have found that *IL-33* can promote the activation of p38, increasing the levels of liver CSC markers expression, and epithelial to mesenchymal transition- (EMT-) like changes [53]. We suppose that *IL-33/ST2* may enhance *CD44* expression to initiate HCC, but further experimentation is required to elucidate the mechanism.

In summary, our genetic results suggest an association between SNPs (*CD44* rs187115, *ST2* rs3821204) and the risk of HCC. The combination of *CD44* rs187115, *IL-33* rs1929992, and *ST2* rs3821204 might be used as a marker to identify a subgroup at higher risk of HCC among the Chinese population. Unfortunately, the signaling pathway for HCC development from *CD44* to *IL-33/ST2* axis has not been reported, and the small sample size of this study may limit the applicability of these results. Therefore, future research will be required, recruiting larger sample sizes, careful design, and more clinical information to identify risk factors for HCC development from *CD44* rs187115, *IL-33* rs1929992, and *ST2* rs3821204 polymorphisms and the underlying biological mechanisms leading to HCC.

Data Availability

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Ethical Approval

The Ethics Committee approved this study of the Affiliated Tumor Hospital of Guangxi Medical University.

Consent

Participants provided written informed consent before the commencement of this study. Participant consent was provided for the publishing of this article.

Conflicts of Interest

The authors have no competing interests to declare.

Authors' Contributions

Min Fang designed the experiment and analyzed and interpreted the data. Xiaolan Pan, Meiqin Li, and Lei Huang carried out the experiments and analyzed and interpreted the data. Xiaolan Pan and Min Fang wrote the manuscript. Xiaolan Pan, Yihua Liang, Zhaodong Huang, and Bo Zhu collected peripheral blood samples. Meiqin Li and Dan Mo performed the data analysis of demographic and clinical characteristics of research participants. All authors drafted, reviewed, edited, read, and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work is appropriately investigated and resolved as required. Xiaolan Pan, Meiqin Li, Lei Huang, Xiaolan Pan, Meiqin Li and Lei Huang contributed equally to this work.

Acknowledgments

This work was supported by grants from the National Science Foundation of China (81760530) and the National Science Foundation of Guangxi (2017GXNSFBA198047). The authors do appreciate all the volunteers who participated in this study.

References

- [1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," *CA: a Cancer Journal for Clinicians*, vol. 68, no. 6, pp. 394–424, 2018.
- [2] L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, "Global cancer statistics, 2012," *CA: a Cancer Journal for Clinicians*, vol. 65, no. 2, pp. 87–108, 2015.
- [3] M. Maluccio and A. Covey, "Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma," *CA: a Cancer Journal for Clinicians*, vol. 62, no. 6, pp. 394–399, 2012.

- [4] J. Bruix, M. Reig, and M. Sherman, "Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma," *Gastroenterology*, vol. 150, no. 4, pp. 835–853, 2016.
- [5] X. Wang, A. Zhang, and H. Sun, "Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma," *Hepatology*, vol. 57, no. 5, pp. 2072–2077, 2013.
- [6] J. H. Zhong, B. D. Xiang, L. Ma, X. M. You, L. Q. Li, and G. S. Xie, "Meta-Analysis of Microsomal Epoxide Hydrolase Gene Polymorphism and Risk of Hepatocellular Carcinoma," *PLoS One*, vol. 8, no. 2, article e57064, 2013.
- [7] Y. J. Jiang, J. H. Zhong, Z. H. Zhou et al., "Association between polymorphisms in microRNA target sites of *RAD51D* genes and risk of hepatocellular carcinoma," *Cancer Medicine*, vol. 8, no. 5, pp. 2545–2552, 2019.
- [8] X. W. Wang, S. P. Hussain, T. I. Huo et al., "Molecular pathogenesis of human hepatocellular carcinoma," *Toxicology*, vol. 181–182, pp. 43–47, 2002.
- [9] G. Fattovich, T. Stroffolini, I. Zagni, and F. Donato, "Hepatocellular carcinoma in cirrhosis: incidence and risk factors," *Gastroenterology*, vol. 127, no. 5, Supplement 1, pp. S35–S50, 2004.
- [10] T. Oikawa, "Cancer stem cells and their cellular origins in primary liver and biliary tract cancers," *Hepatology*, vol. 64, no. 2, pp. 645–651, 2016.
- [11] K. Nio, T. Yamashita, and S. Kaneko, "The evolving concept of liver cancer stem cells," *Molecular Cancer*, vol. 16, no. 1, 2017.
- [12] A. Pietras, A. M. Katz, E. J. Ekström et al., "Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth," *Cell Stem Cell*, vol. 14, no. 3, pp. 357–369, 2014.
- [13] L. Wang, X. Zuo, K. Xie, and D. Wei, "The role of CD44 and cancer stem cells," *Methods in Molecular Biology*, vol. 1692, pp. 31–42, 2018.
- [14] H. Dang, S. N. Steinway, W. Ding, and C. B. Rountree, "Induction of tumor initiation is dependent on CD_{44s} in c-Met⁺ hepatocellular carcinoma," *BMC Cancer*, vol. 15, no. 1, 2015.
- [15] H. Okabe, T. Ishimoto, K. Mima et al., "CD44s signals the acquisition of the mesenchymal phenotype required for anchorage-independent cell survival in hepatocellular carcinoma," *British Journal of Cancer*, vol. 110, no. 4, pp. 958–966, 2014.
- [16] R. G. Simonetti, C. Camma, F. Fiorello, F. Politi, G. D'Amico, and L. Pagliaro, "Hepatocellular carcinoma. A worldwide problem and the major risk factors," *Digestive Diseases and Sciences*, vol. 36, no. 7, pp. 962–972, 1991.
- [17] C. Bouffi, M. Rochman, C. B. Zust et al., "IL-33 markedly activates murine eosinophils by an NF- κ B-dependent mechanism differentially dependent upon an IL-4-driven autoinflammatory loop," *Journal of Immunology*, vol. 191, no. 8, pp. 4317–4325, 2013.
- [18] T. Mchedlidze, M. Waldner, S. Zopf et al., "Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis," *Immunity*, vol. 39, no. 2, pp. 357–371, 2013.
- [19] M. Fang, Y. Li, K. Huang et al., "IL33 promotes colon cancer cell stemness via JNK activation and macrophage recruitment," *Cancer Research*, vol. 77, no. 10, pp. 2735–2745, 2017.
- [20] B. A. Runyon and AASLD, "Introduction to the revised American Association for the Study of Liver Diseases practice guideline management of adult patients with ascites due to cirrhosis 2012," *Hepatology*, vol. 57, no. 4, pp. 1651–1653, 2013.
- [21] Y. L. Huang, J. R. Wu, M. Fang et al., "The role of ERCC1 and AFP gene polymorphism in hepatocellular carcinoma," *Medicine*, vol. 98, no. 14, article e15090, 2019.
- [22] O. Mayo, "A century of Hardy-Weinberg equilibrium," *Twin Research and Human Genetics*, vol. 11, no. 3, pp. 249–256, 2008.
- [23] Z. Li, Z. Zhang, Z. He et al., "A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (<http://analysis.bio-x.cn>)," *Cell Research*, vol. 19, no. 4, pp. 519–523, 2009.
- [24] J. Zhu, W. Fu, W. Jia, H. Xia, G. C. Liu, and J. He, "Association between NER pathway gene polymorphisms and Wilms tumor risk," *Molecular Therapy-Nucleic Acids*, vol. 12, pp. 854–860, 2018.
- [25] Y. Liu, H. Qing, X. Su, C. Wang, Z. Li, and S. Liu, "Association of CD44 gene polymorphism with survival of NSCLC and risk of bone metastasis," *Medical Science Monitor*, vol. 21, pp. 2694–2700, 2015.
- [26] T. Winder, Y. Ning, D. Yang et al., "Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma," *International Journal of Cancer*, vol. 129, no. 5, pp. 1096–1104, 2011.
- [27] S. Goodison, V. Urquidi, and D. Tarin, "CD44 cell adhesion molecules," *Molecular Pathology*, vol. 52, no. 4, pp. 189–196, 1999.
- [28] J. Weng, X. Han, K. Liu et al., "CD44 3'-untranslated region functions as a competing endogenous RNA to enhance NK Sensitivity of Liver Cancer Stem Cell by Regulating ULBP2 Expression," *International journal of biological sciences*, vol. 15, no. 8, pp. 1664–1675, 2019.
- [29] N. R. Park, J. H. Cha, J. W. Jang et al., "Synergistic effects of CD44 and TGF- β 1 through AKT/GSK-3 β / β -catenin signaling during epithelial-mesenchymal transition in liver cancer cells," *Biochemical and Biophysical Research Communications*, vol. 477, no. 4, pp. 568–574, 2016.
- [30] R. Asai, H. Tsuchiya, M. Amisaki et al., "CD44 standard isoform is involved in maintenance of cancer stem cells of a hepatocellular carcinoma cell line," *Cancer Medicine*, vol. 8, no. 2, pp. 773–782, 2019.
- [31] Z. E. Sauna, C. Kimchi-Sarfaty, S. V. Ambudkar, and M. M. Gottesman, "Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer," *Cancer Research*, vol. 67, no. 20, pp. 9609–9612, 2007.
- [32] B. Chen, C. Yi, J. Wang et al., "A comprehensive study of CD44 rs 187115 variant and cancer risk in a central Chinese population," *Journal of Cellular Biochemistry*, vol. 120, no. 8, pp. 12949–12957, 2019.
- [33] Y. E. Chou, M. J. Hsieh, H. L. Chiou, H. L. Lee, S. F. Yang, and T. Y. Chen, "CD44 gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathologic features," *BioMed Research International*, vol. 2014, Article ID 231474, 9 pages, 2014.
- [34] S. Ali, A. Mohs, M. Thomas et al., "The dual function cytokine IL-33 interacts with the transcription factor NF- κ B to dampen NF- κ B-stimulated gene transcription," *Journal of Immunology*, vol. 187, no. 4, pp. 1609–1616, 2011.
- [35] M. S. Kim, E. Kim, J.-S. Heo et al., "Circulating IL-33 level is associated with the progression of lung cancer," *Lung Cancer*, vol. 90, no. 2, pp. 346–351, 2015.

- [36] X. Zhu, L. Xie, H. Qin et al., "Interaction between IL-33 gene polymorphisms and current smoking with Susceptibility to Systemic Lupus Erythematosus," *Journal of immunology research*, vol. 2019, Article ID 1547578, 5 pages, 2019.
- [37] W. Xu, Y. Liu, and D. Ye, "Association between IL-33 gene polymorphisms (rs1929992, rs7044343) and systemic lupus erythematosus in a Chinese Han population," *Immunological Investigations*, vol. 45, no. 7, pp. 575–583, 2016.
- [38] S. S. Koca, Y. Pehlivan, M. Kara et al., "The IL-33 gene is related to increased susceptibility to systemic sclerosis," *Rheumatology International*, vol. 36, no. 4, pp. 579–584, 2016.
- [39] A. Jafarzadeh, K. Minaee, A. R. Farsinejad et al., "Evaluation of the circulating levels of IL-12 and IL-33 in patients with breast cancer: influences of the tumor stages and cytokine gene polymorphisms," *Iranian Journal of Basic Medical Sciences*, vol. 18, no. 12, pp. 1189–1198, 2015.
- [40] X. Liu, L. Zhu, X. Lu et al., "IL-33/ST2 pathway contributes to metastasis of human colorectal cancer," *Biochemical and Biophysical Research Communications*, vol. 453, no. 3, pp. 486–492, 2014.
- [41] P. Zhang, X. K. Liu, Z. Chu et al., "Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications," *The Journal of International Medical Research*, vol. 40, no. 5, pp. 1654–1661, 2012.
- [42] F. Bai, F. Ba, Y. You et al., "Decreased ST2 expression is associated with gastric cancer progression and pathogenesis," *Oncology Letters*, vol. 17, no. 6, pp. 5761–5767, 2013.
- [43] P. Sowa, M. Misiolek, M. Zielinski, B. Mazur, and M. Adamczyk-Sowa, "Novel interleukin-33 and its soluble ST2 receptor as potential serum biomarkers in parotid gland tumors," *Experimental Biology and Medicine*, vol. 243, no. 9, pp. 762–769, 2018.
- [44] J. F. Zhang, P. Wang, Y. J. Yan et al., "IL-33 enhances glioma cell migration and invasion by upregulation of MMP2 and MMP9 via the ST2-NF- κ B pathway," *Oncology Reports*, vol. 38, no. 4, pp. 2033–2042, 2017.
- [45] D. Bergis, V. Kassis, A. Ranglack et al., "High serum levels of the Interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma," *Translational Oncology*, vol. 6, no. 3, pp. 311–318, 2013.
- [46] Z. H. Wei, Y. Y. Li, S. Q. Huang, and Z. Q. Tan, "Genetic variants in IL-33/ST2 pathway with the susceptibility to hepatocellular carcinoma in a Chinese population," *Cytokine*, vol. 118, pp. 124–129, 2019.
- [47] F. Wu, L. Li, Q. Wen et al., "A functional variant in ST2 gene is associated with risk of hypertension via interfering miR-202-3p," *Journal of Cellular and Molecular Medicine*, vol. 21, no. 7, pp. 1292–1299, 2017.
- [48] K. D. Mertz, L. F. Mager, M. H. Wasmer et al., "The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice," *Oncoimmunology*, vol. 5, no. 1, article e1062966, 2016.
- [49] M. El-Bendary, D. Nour, M. Arafa, and M. Neamatallah, "Methylation of tumour suppressor genes RUNX3, RASSF1A and E-Cadherin in HCV-related liver cirrhosis and hepatocellular carcinoma," *British Journal of Biomedical Science*, vol. 77, no. 1, pp. 35–40, 2020.
- [50] F. Liu, Z. Liao, J. Song et al., "Genome-wide screening diagnostic biomarkers and the construction of prognostic model of hepatocellular carcinoma," *Journal of Cellular Biochemistry*, vol. 121, no. 3, pp. 2582–2594, 2020.
- [51] R. Zhao, Z. Yu, M. Li, and Y. Zhou, "Interleukin-33/ST2 signaling promotes hepatocellular carcinoma cell stemness expansion through activating c-Jun N-terminal Kinase pathway," *The American Journal of the Medical Sciences*, vol. 358, no. 4, pp. 279–288, 2019.
- [52] H. Hu, J. Sun, C. Wang et al., "IL-33 facilitates endocrine resistance of breast cancer by inducing cancer stem cell properties," *Biochemical and Biophysical Research Communications*, vol. 485, no. 3, pp. 643–650, 2017.
- [53] C. Xie, J. Zhu, X. Wang et al., "Tobacco smoke induced hepatic cancer stem cell-like properties through IL-33/p38 pathway," *Journal of Experimental & Clinical Cancer Research*, vol. 38, no. 1, 2019.